C Reactive Protein Testing Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

C-reactive protein testing detects inflammation caused by a range of conditions including bacterial infections, autoimmune disorders, and cardiovascular diseases. High-sensitivity CRP (hs-CRP) testing has expanded the market by enabling more precise cardiovascular risk stratification, while conventional CRP assays remain staples in acute care settings worldwide.

• •Tests are performed using immunoassay, nephelometry, and turbidimetric methods across hospital labs, reference laboratories, and point-of-care devices
• •Demand is fueled by the global burden of infectious diseases, rising autoimmune disorder prevalence, and growing use of inflammatory biomarkers in chronic disease management
• •Reimbursement support and established clinical guidelines for CRP-based decision-making have solidified its role in standard diagnostic pathways

The aging global population and associated rise in chronic inflammatory and lifestyle-related diseases are primary factors propelling market expansion. Increasing healthcare spending, particularly in emerging economies, along with the proliferation of point-of-care testing infrastructure, is making CRP testing more accessible across diverse care settings.

• •Cardiovascular disease prevention programs increasingly rely on hs-CRP as a risk stratification tool, driving demand in preventive and primary care
• •Rising awareness of inflammation's role in metabolic disorders, diabetes, and neurodegenerative diseases is broadening clinical applications
• •Technological advances in rapid immunoassay platforms and microfluidic devices are reducing turnaround times and expanding point-of-care adoption

The market is segmented by assay type, end user, and geography, with immunoassay-based platforms commanding the largest share due to their accuracy, automation compatibility, and established laboratory workflows. North America currently leads in market revenue, supported by advanced healthcare infrastructure and high diagnostic testing volumes, while the Asia-Pacific region is expected to grow at the fastest pace.

• •By assay type, immunoturbidimetric and nephelometric methods dominate laboratory settings, while lateral flow and cartridge-based assays are gaining share in point-of-care environments
• •Hospitals and diagnostic laboratories represent the largest end-user segment, though clinics and physician offices are growing with decentralized testing trends
• •Asia-Pacific, Latin America, and the Middle East offer the strongest growth opportunities due to improving healthcare access, rising disease burden, and laboratory modernization initiatives

What are the recent trends and outlook?

Emerging trends include the integration of CRP testing with multiplex inflammatory panels, the adoption of artificial intelligence for result interpretation and clinical decision support, and the miniaturization of testing platforms for use in non-traditional settings such as pharmacies and home care. As healthcare systems globally prioritize early disease detection and preventive care, CRP testing is positioned for sustained growth throughout the forecast period.

• •High-sensitivity CRP assays are being increasingly paired with other biomarkers such as troponin and BNP in comprehensive cardiovascular risk panels
• •Laboratory automation and digital connectivity are enabling real-time result reporting and integration with electronic health record systems
• •Point-of-care CRP testing is expanding in outpatient and community settings, driven by the need for rapid triage decisions in respiratory and infectious disease management